Elicio Therapeutics, Inc. · NASDAQ:ELTX
Elicio Therapeutics — Corporate Update (June 2026)
16 slides from Elicio Therapeutics's corporate update, Jun 15, 2026
Slide 1: AMPLIFY-7P: Defining the Path Forward for ELI-002 7P in Adjuvant mKRAS PDAC
AMPLIFY-7P Defining the Path Forward for ELI-002 7P in Adjuvant mKRAS PDAC JUNE 15, 2026
Slide 2: Disclaimers
Disclaimers No Representation or Warranty We do not make and hereby expressly disclaim any representation or warranty, express or implied, as to the reasonableness of the assumptions made in the Presentation or the accuracy or completeness of the information contained in or incorporated by reference
Slide 3: AMPLIFY-7P Identified a Clear Phase 3 Development Path for ELI-002 7P
DFS curves separated early during active ELI-002 7P treatment, supporting biological activity in the adjuvant setting Strong treatment effect observed in lower residual disease patient populations, supporting a more focused development strategy Strong mKRAS-specific immune responses correlated with
Slide 4: AMPLIFY-7P: Randomized Phase 2 Trial in Adjuvant mKRAS+ PDAC
AMPLIFY-7P: Randomized Phase 2 Trial in Adjuvant mKRAS+ PDAC 4 CLINICAL STUDY OVERVIEW: NCT05726864 (2:1 Randomized) Note: DFS assessment by iRECIST (new lesions confirmed by biopsy/imaging); R0/R1: Absence or presence of microscopic residual disease; NED: No Evidence of Disease. MRD: Minimal Residu
Slide 5: Early DFS Separation Observed Through 9 Months
Early DFS Separation Observed Through 9 Months 1 5 Post-hoc 3-month and 6-month landmark analyses indicate early clinical activity, with treatment-arm separation persisting through 9 months Su rv iv al P ro ba bi li ty ELI-002 7P DFS: ITT Stratified 20-APR-2026DCO 23.8 (9.8, NE)ELI-002 7P Median DFS
Slide 6: Stronger Treatment Effect Observed in Lower Residual Disease Patient Population
Stronger Treatment Effect Observed in Lower Residual Disease Patient Population 1 6 Post-hoc analyses demonstrate stronger treatment effect in lower residual disease Clear improvement in DFS hazard ratio observed in R0 resected patients (N=121). While post-hoc, these analyses clearly identify the po
Slide 7: Resection Margin Status Was Imbalanced at Baseline
Higher Recurrence Risk Lower Recurrence Risk Resection Margin Status Was Imbalanced at Baseline 7 The ELI-002 7P arm contained more high recurrence-risk R1 patients than the observation arm Total (N=144) SOC (N=48) ELI-002 7P (N=96)Characteristic 23 (16%)5 (10%)18 (19%)Resection margin R1 19% 10% 0
Slide 8: Stronger Treatment Effect Observed in Lower Residual Disease Patient Population
Stronger Treatment Effect Observed in Lower Residual Disease Patient Population 1 8 Post-hoc analyses demonstrate stronger treatment effect in lower residual disease ITT HR = 0.79 P = 0.2492, N = 144 R0 Resected HR = 0.65 P = 0.0484, N = 121 The analyses show the potential for improved treatment eff
Slide 9: mKRAS-Specific T Cell Responses Were Strongly Associated with Improved DFS
mKRAS-Specific T Cell Responses Were Strongly Associated with Improved DFS 9 Greater mKRAS-specific T cell responses were associated with longer DFS following ELI-002 7P treatment 0 3 6 9 12 15 18 21 24 27 30 0 25 50 75 100 Months from randomization D FS P ro ba bi lit y ELI-002 7P DFS: ITT Supervis
Slide 10: ELI-002 7P Demonstrated a Favorable Safety and Tolerability Profile
ELI-002 7P Demonstrated a Favorable Safety and Tolerability Profile 10 Safety profile supports extended treatment and combination strategies Proportionally Fewer Adverse Events Observed vs. SOC • Proportionally fewer ELI-002 7P patients had adverse events (AEs), Grade ≥3 AEs, and Serious AEs • 5% ha
Slide 11: A Precision Medicine Roadmap to Adjuvant PDAC Pivotal Phase 3
A Precision Medicine Roadmap to Adjuvant PDAC Pivotal Phase 3 11 Key Phase 2 findings inform the Phase 3 development strategy Robust early efficacy during the dosing period with DFS separation maintained through 9 months Strong efficacy signal in completely resected R0 patients consistent with lower
Slide 12: A Substantial Post-Surgical Treatment Gap Remains in Adjuvant PDAC
Phase 2: R0 ~84% (121/144) A Substantial Post-Surgical Treatment Gap Remains in Adjuvant PDAC Observation remains standard of care despite substantial recurrence risk after surgery and chemotherapy 12 1 Leonhardt CS, et al. Gastroenterology. 2024, 2 Kleeff J, et al. Ann. Surgery. 2007, 3 Daamen LA,
Slide 13: Selection of R0 Resected Patients Offers a Clear Phase 3 Development Strategy
Selection of R0 Resected Patients Offers a Clear Phase 3 Development Strategy 13 R0 resected disease setting selects for lower disease burden and slower recurrence kinetics R1 ResectionR0 ResectionFeature Microscopic tumor presentMicroscopic tumor not presentSurgical Margin Status ↑ Higher↓ LowestRe
Slide 14: Biology of R1 Resected PDAC is Distinct from R0 Resected
Biology of R1 Resected PDAC is Distinct from R0 Resected 14 R1 margins found in ~20% of PDAC resections indicate unique biology of disease underlying increased recurrence risk 1 Hernandez, et al. Annals Surg. 2009; 2Tummers, et al. Br J Surg. 2019; 3 Esposito, et al. Annals Surg Oncol. 2008 17 patie
Slide 15: Next Steps
Next Steps 15 01 02 Engage with FDA: End-of-Phase 2 Meeting Align with FDA on Phase 3 design & regulatory strategy: ELI-002 7P in R0 resected adjuvant mKRAS PDAC Initiate Phase 3 Study in Adjuvant PDAC Post FDA alignment, initiate Phase 3, subject to funding Phase 2 results support continued regulat
Slide 16: Elicio Therapeutics
‘Delicio THERAPE UTICS